The biggest promise for PD-1 blockers--both clinically and commercially--likely lies in combination therapies,
in a 35 billion a year field!!
Well Hello...roche pd-1 plus cobimetinib!!!!!
They already discussed recently the approval consideration of more cancer meds based on pfs...we doubled that of prednisone....these patients in comet were able to seek other therapies after pred. This is what destroyed this trial...after comet failed i think the patients were already to far gone and possibly they accepted their fate or too far gone that other therapies were of little use...with additional bone data and other oncologist lobbying for cabo their could be a chance....remember politics is involved in every aspect of life...if the onco's with influence weigh in, it could make a difference.
true this is the future, but I feel encouraged by Dr. Posado's patients where 7of 8 responded.....and where we are questioning if the patients are too advanced...in his trial the most advanced patient did the best!!! its going to be a nail biter to the finish
Not sure if its a retread
Citation: The PLOS ONE Staff (2014) Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE 9(8): e106797. doi:10.1371/journal.pone.0106797
Published: August 21, 2014
Copyright: © 201
Clearly all of the positive energy flowing our way is working its magic. I have not seen Eva with this much energy for more than a year. She is now almost halfway through her second round of the cabozantinib and she is absolutely glowing. The tumour mass on her shoulder continues to shrink, her bloodtests are excellent and even her appetite is starting to increase. She runs rings around the lot of us.
If you read or keep up with Ohad Hammers blog...he states results in October timeframe for comet...he says these are the experts opinions
Asco interview asking doctor Guru what trial has him excited in the treatment for RCC...can anyone guess???lol
Ernie, after interim analysis didn't exelixis say they would have final results around yr. end? If that's true then we wouldn't be overdue yet...but I am not sure if they were speaking in generalities or if I was misunderstood or if I was smoking the heavy stuff that day
Iwould go with what ernie referred to...exel said fhey will not sit on data...also they stated in their C.C. that sales were increasing bcuz pafients r staying on the drug longer...to me says living longer and better mgmt of side effecfs...i would have to assume lots of patients have had their dose reduced which is fhe best strategy since lower dose does not seem to be less efficacious